Stephen C. Glover - 18 May 2023 Form 4 Insider Report for Ambrx Biopharma Inc.

Role
Director
Signature
/s/ Sonja Nelson, Attorney-in-Fact for Stephen Glover
Issuer symbol
N/A
Transactions as of
18 May 2023
Net transactions value
$0
Form type
4
Filing time
09 Jun 2023, 16:17:34 UTC
Previous filing
13 Dec 2022
Next filing
18 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMAM Ordinary Shares Award $0 +85,000 $0.000000 85,000 07 Jun 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMAM Stock Option (right to buy) Award $0 +40,000 $0.000000 40,000 07 Jun 2023 Ordinary Shares 40,000 $1.96 Direct F1, F3, F4
transaction AMAM Stock Option (right to buy) Award $0 +17,500 $0.000000 17,500 18 May 2023 Ordinary Shares 17,500 $1.97 Direct F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares of the Issuer may be represented by the Issuer's American Depositary Shares ("ADSs"). Each ADS represents seven (7) Ordinary Shares of the Issuer.
F2 Represents grant of Restricted Stock Units (the "RSUs") payable solely in Ordinary Shares of the Issuer that vest as follows: on the earlier of (i) the one year anniversary of the date of grant and (ii) the day before the next annual general meeting.
F3 The exercise price of the options is equal to the fair market value per ordinary share on the grant date based on the trading price of the ADS.
F4 The options vest on June 7, 2024.
F5 The options vested on June 6, 2023.